BCAX
NASDAQBicara Therapeutics Inc.
Price$27.74+0.10 (+0.36%)
01:30 PM07:45 PM
News · 26 weeks85-50%
2026-01-182026-07-12
Mix3890d
- Insider18(47%)
- SEC Filings9(24%)
- Other7(18%)
- Earnings2(5%)
- Offering1(3%)
- Analyst1(3%)
Latest news
25 items- INSIDERChief Executive Officer Mazumdar Claire exercised 10,000 shares at a strike of $3.79 and sold $284,198 worth of shares (10,000 units at $28.42) as part of a pre-agreed trading plan (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERChief Financial Officer Hyep Ivan exercised 12,500 shares at a strike of $3.79 and sold $807,672 worth of shares (28,000 units at $28.85) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 129,855 units (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERPresident and COO Cohlhepp Ryan exercised 18,750 shares at a strike of $3.79 and sold $833,129 worth of shares (28,750 units at $28.98) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 181,641 units (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- SECSEC Form 144 filed by Bicara Therapeutics Inc.144 - Bicara Therapeutics Inc. (0002023658) (Subject)
- PRBicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on July 1, 2026 to four new employees under Bicara’s 2026 Inducement Plan as a material inducement to employment. The employees received, in the aggregate, non-qualified stock options to purchase 191,425 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $28.91 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq on July 1, 2026. One-fourth of the shares vest on th
- INSIDERSEC Form 4 filed by Director Ra Capital Management, L.P.4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERSEC Form 4 filed by Director Bowden Christopher4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERSEC Form 4 filed by Director Haviland Kate4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERSEC Form 4 filed by Director Mazumdar-Shaw Kiran4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERSEC Form 4 filed by Director Robertson Scott M.4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERSEC Form 4 filed by Director Powell Michael4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERSEC Form 4 filed by Director Simson Jake4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- SECBicara Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Bicara Therapeutics Inc. (0002023658) (Filer)
- SECSEC Form 144 filed by Bicara Therapeutics Inc.144 - Bicara Therapeutics Inc. (0002023658) (Subject)
- INSIDERChief Financial Officer Hyep Ivan exercised 9,200 shares at a strike of $3.79 and sold $187,883 worth of shares (9,200 units at $20.42) as part of a pre-agreed trading plan (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- SECBicara Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Bicara Therapeutics Inc. (0002023658) (Filer)
- PRFicerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCCAt a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely to remain progression-free and alive Company to h
- INSIDERChief Executive Officer Mazumdar Claire exercised 15,000 shares at a strike of $3.79 and sold $300,579 worth of shares (15,000 units at $20.04) as part of a pre-agreed trading plan (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERPresident and COO Cohlhepp Ryan exercised 8,000 shares at a strike of $3.79 and sold $253,649 worth of shares (12,500 units at $20.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 191,641 units (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.SCHEDULE 13G/A - Bicara Therapeutics Inc. (0002023658) (Subject)
- SECSEC Form SCHEDULE 13G filed by Bicara Therapeutics Inc.SCHEDULE 13G - Bicara Therapeutics Inc. (0002023658) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.SCHEDULE 13G/A - Bicara Therapeutics Inc. (0002023658) (Subject)
- PRBicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective May 8, 2026, it awarded an inducement grant to Christopher Sarchi under Bicara's 2026 Inducement Plan as a material inducement to his commencement of employment as Bicara's Chief Commercial Officer. Mr. Sarchi received a non-qualified stock option to purchase 282,240 shares of Bicara's common stock, par value $0.0001 per share, with an exercise price of $22.58 per share, equal to the closing price of Bicara's common stock as reported by Nasdaq on
- INSIDERSEC Form 4 filed by Chief Medical Officer Schelman William4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERSEC Form 3 filed by new insider Schelman William3 - Bicara Therapeutics Inc. (0002023658) (Issuer)
BCAX FAQ
6 questionsWhere does BCAX stock trade?
Bicara Therapeutics Inc. (BCAX) is listed on NASDAQ.What sector and industry is BCAX in?
Bicara Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Bicara Therapeutics Inc. go public?
Bicara Therapeutics Inc. (BCAX) completed its IPO in 2024.What are analysts saying about BCAX?
Bicara Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $4200.00 price target on 2026-05-11.What companies are similar to BCAX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare BCAX side-by-side with any of them on Quantisnow.How can I track BCAX on Quantisnow?
Quantisnow aggregates Bicara Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BCAX to receive live email and push alerts on every new disclosure.